ScreenerHero

EWTXEdgewise Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · edgewisetx.com
44.18USD-4.87%Mkt Cap: 4.80B $P/E: —

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small mole…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified?

How Edgewise Therapeutics Stock Has Been Trading Recently Edgewise Therapeutics (EWTX) has drawn investor attention after a period of mixed short term trading, with the stock down 2.4% over the past day but higher over the past month and past 3 months. Shares last closed at US$38.81, with the company’s total return up about 63% year to date and a much larger gain over the past year. These figures prompt closer scrutiny of what is currently priced into the stock. See our latest analysis for...

Simply Wall St.
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?

VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.

Zacks
Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive
Pharmaceutical Technology
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?
IInsider Monkey
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data
IInsider Monkey
Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says
MMT Newswires
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?
Investor's Business Daily
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
Benzinga
SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall
Investing.com
Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move
Simply Wall St.
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
Zacks
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Pharmaceutical Technology
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang
Investor's Business Daily
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business
Stocktwits
Servier buys into muscular dystrophy with potentially $2.7B deal
BioPharma Dive